← board
NEUP
distress 6/10 · elevated risk$4.00+20%today-80% from 52w high
Lead: social anxiety disorder
Revenue
$16M
Liquidity
$19M
Runway
—
Shares 1y
+129%
Price & events
-4.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+20.1%
1D
+13.3%
1W
-8.3%
1M
-18.5%
3M
-4.5%
6M
-51.2%
1Y
-55.6%
2Y
—
5Y
-97.7%
All
Overview
- Market Cap
- $21.62M
- Volume
- 5.72M
- 52 Week Range
- $3.30 – $20.00
- Total Shares
- 5.40M
- Float Shares
- 4.19M
- Short %
- 0.29%
- % Held by Insiders
- 7.70%
- % Held by Institutions
- 55.03%
- RVOL
- 21.00x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- by year-endconferencedata presentationsecondaryStrategic review updateSEC 8-K
- 2025-10-20trial discontinuedBNC210 · Discontinued further development of SAD programSEC 8-K
- October 20, 2025readoutPhase 3BNC210 · Topline results from AFFIRM-1 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-15HC Wainwright & Co.Buy → Neutral
- 2025-12-05HC Wainwright & Co.Buy
- 2025-09-11Maxim GroupBuy
- 2025-08-26HC Wainwright & Co.Buy
- 2025-02-04HC Wainwright & Co.Buy
Competitors — social anxiety disorder
Recent news
- 2026-07-23Scancell agrees to buy Neuphoria, combined firm set to list on Nasdaq - marketscreener.com
- 2026-07-23Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing - The Manila Times
- 2026-07-21Price to book forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
- 2026-07-15Neuphoria Therapeutics (NEUP) Slips 1.26% as Stock Tests Key Support Zone - Volume Nodes - dars.gov.et
- 2026-07-15Neuphoria announces initiation of strategic review - MSN
- 2026-06-26Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc - GlobeNewswire
- 2026-06-26Scancell confirms advanced talks on takeover of Neuphoria; eyes Nasdaq - London South East
- 2026-06-26Scancell in talks for reverse merger with Neuphoria Therapeutics - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.